FMP
GE HealthCare Technologies Inc.
GEHC
NASDAQ
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, as well as women's health products. The Ultrasound segment provides screening, diagnosis, treatment, and monitoring of certain diseases through radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment involved in the provision of medical devices, consumable products, services, and digital solutions through patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal infant care products. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals, administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents, or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes that are injected into a patient prior to a diagnostic imaging scan. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
87.34 USD
2.6 (2.98%)
Tony Dante
Oct 30, 2024
GE HealthCare Technologies Inc. (NASDAQ:GEHC) is a prominent player in the healthcare sector, specializing in medical imaging, monitoring, biomanufacturing, and cell and gene therapy technologies. The company competes with other major healthcare technology firms, striving to innovate and improve patient care. GEHC's recent financial performance reflects its strategic efforts to maintain a competitive edge. On October 30, 2024, GEHC reported earnings per share (EPS) of $1.14, exceeding the Zacks...
Zacks Investment Research
Aug 20, 2024
GE HealthCare's (GEHC) latest collaboration is likely to equip clinicians with a toolset to deliver enhanced care to female patients and improve the patient experience.
InvestorPlace
Aug 7, 2024
Markets tanked on Monday because the Japanese central bank raised its interest rate to 0.25%. Interest rates were originally at a benchmark between 0 and 0.1, meaning a minor 15- to 25-basis-point increase had significant consequences for investors who were making margin calls with Yen.
Seeking Alpha
Aug 6, 2024
GE HealthCare's Q2 earnings were disappointing, with revenue stagnating and cost efficiencies driving earnings, leading to a lowered price target and sell rating. The company continues to lag behind the market in various healthcare sectors, with AI potential diminishing and a decreased focus on R&D. Upside potential lies in the healthcare market and AI technology, but GEHC's slow progress and competition pose challenges for future growth.
Zacks Investment Research
Aug 2, 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Davit Kirakosyan
Jul 31, 2024
GE HealthCare (NASDAQ:GEHC) shares rose more than 2% on Wednesday after the company reported stronger-than-expected second-quarter earnings, but reduced full-year outlook, primarily impacted by challenges in the Chinese market. The medical technology company posted adjusted earnings per share (EPS) of $1.00, exceeding Street expectations by $0.02. However, revenue was slightly below the anticipated $4.87 billion, coming in at $4.84 billion. The revenue shortfall was attributed to difficulties in...
Zacks Investment Research
Jul 31, 2024
GE HealthCare's (GEHC) second-quarter results witness declining segmental revenues in imaging, ultrasound and patient care. The bottom line improves on better pricing.
Investopedia
Jul 31, 2024
GE HealthCare (GEHC) shares rose over 4% in early trading Wednesday after the company reported second-quarter profits that beat analysts' estimates.
Zacks Investment Research
Jul 31, 2024
While the top- and bottom-line numbers for GE HealthCare (GEHC) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks Investment Research
Jul 31, 2024
GE HealthCare Technologies (GEHC) came out with quarterly earnings of $1 per share, beating the Zacks Consensus Estimate of $0.98 per share. This compares to earnings of $0.92 per share a year ago.